Landfar(SZ:000504) Zheng Quan Zhi Xing·2025-08-11 13:08Overview of the Transaction - The company plans to acquire 51% equity of Hunan Huize Biomedical Technology Co., Ltd. in cash, which will make Huize a subsidiary and included in the consolidated financial statements [1][2] - The acquisition aims to enhance the company's industrial chain layout by leveraging Huize's technology and customer resources in drug research and clinical evaluation, which are highly synergistic with the company's existing biopharmaceutical business [2][10] - The agreement signed is a preliminary intention agreement and does not involve specific contract amounts; it is subject to further negotiation and due diligence [2][9] Parties Involved - The transferors include individuals and partnerships that do not have any related party relationships with the company and are not listed as dishonest executors [3][4][5] Target Company Information - Hunan Huize Biomedical Technology Co., Ltd. is a specialized CRO company focused on drug research and clinical evaluation, with over 85% of its revenue coming from clinical evaluation services [5][6] - The company has established long-term partnerships with over 300 domestic and international pharmaceutical companies and research institutions, completing more than 1,000 technical service projects [6][10] Financial and Operational Aspects - The registered capital of Huize is approximately 11.1 million yuan, and it has been recognized as a national high-tech enterprise and a key "little giant" enterprise [5][6] - The main business includes drug wholesale and retail, clinical trial services, and various technical services related to medical research and development [5][6] Purpose and Impact of the Acquisition - The acquisition is expected to enhance the company's biopharmaceutical segment, improve profitability, and strengthen risk resistance [10] - It will also integrate clinical transformation research and drug development, leading to improved operational efficiency and significant synergies [10] - Overall, the transaction is aligned with the company's strategic development needs and aims to foster long-term sustainable growth [10]